Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …

Background Major classes of medical therapy for heart failure with reduced ejection fraction
(HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan …

Aims Despite well‐established benefits of sacubitril/valsartan for cardiac reverse
remodelling and the prognosis of patients with heart failure with reduced ejection fraction …

Background Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure
with reduced ejection fraction (HFrEF) are often not reached in clinical practice. Objectives …

Background: While disease-modifying therapies exist for heart failure (HF) with reduced left
ventricular ejection fraction (LVEF), few options are available for patients in the higher range …

Aims Sacubitril/valsartan improves morbidity and mortality in patients with heart failure and
reduced ejection fraction (HFrEF). Whether initiation of sacubitril/valsartan limits the use and …

Background Sacubitril/valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the
risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on …

Objectives: This paper aims to compare the effectiveness of sacubitril-valsartan and
angiotensin-converting enzyme inhibitor (ACE)/angiotensin receptor blocker (ARB) in …